Small joint arthritis presents a large societal burden throughout Europe. The largest pan-European study on osteoarthritis (OA) of the hand observed an average incidence of 16.3%1. As a result of increased life expectancy, and people remaining active longer in life, the incidence of OA in small joints is progressively increasing. To put this into context, joint reconstruction represented 59% of revenue from orthopaedic implants in Western Europe in 2013-14, 5% of which was reconstruction of the extremities2. This is expected to rise to 18% by 20212. Modern Technology has placed increased demands on the hand joint, and this potentially presents problems for the younger generation, who regularly use handheld devices. APRICOT aims to develop a radically new type of implant for the treatment of small joint arthritis. It is minimally invasive, bone conserving and suitable for patients of all ages.
D. Pereira, B. Peleteiro, J. Araújo, J. Branco, R.A. Santos, E. Ramos, 2011. ‘The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review’, Osteoarthritis and Cartilage, 19 (11), pp. 1270-1285, doi: 10.1016/j.joca.2011.08.009. ↩
Frost & Sullivan, 2014. ‘Analysis of the Global Orthopedic Implant Market: Potential Growth in a Mature Market’, Report Number: ND61-54, Frost & Sullivan, California, USA. ↩
Restoring the natural range of motion of the finger joints, APRICOT will go beyond current implant solutions, helping patients return to their normal day-to-day lives. APRICOT will have a significant societal impact potentially reducing the burden of pain for millions of OA sufferers and relieving healthcare systems as a whole.Professor Martin Browne, PhD